Farletuzumab

Farletuzumab, also known as MORAb-003 , constitutes a humanized monoclonal antibody with an affinity for the folate receptor a. In laboratory settings, farletuzumab exhibits the capacity to impede folate receptor a-dependent cell proliferation while instigating tumor cell destruction through complement-dependent cytotoxicity and antibody-dependent cytotoxicity mechanisms. Further bolstering its therapeutic potential, evidence suggests that farletuzumab restrains tumor growth by hindering lyn kinase phosphorylation mediated by folate receptor a. Notably, comprehensive immunohistochemical analyses conducted on human and primate tissues affirm the specificity of farletuzumab's binding to its target, displaying an absence of cross-reactivity with normal tissues.